| Early Stage HER2-Positive Breast Carcinoma
Perjeta vs Kadcyla
Side-by-side clinical, coverage, and cost comparison for early stage her2-positive breast carcinoma.Deep comparison between: Perjeta vs Kadcyla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKadcyla has a higher rate of injection site reactions vs Perjeta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kadcyla but not Perjeta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Perjeta
Kadcyla
At A Glance
IV infusion
Every 3 weeks
HER2/neu receptor antagonist
IV infusion
Every 3 weeks
HER2-targeted antibody-drug conjugate
Indications
- Carcinoma breast stage IV
- Locally Advanced Breast Carcinoma
- Inflammatory Breast Carcinoma
- Early Stage HER2-Positive Breast Carcinoma
- Metastatic HER2-Positive Breast Carcinoma
- Early Stage HER2-Positive Breast Carcinoma
Dosing
Carcinoma breast stage IV Initial 840 mg IV over 60 min, then 420 mg IV every 3 weeks; administered with trastuzumab and docetaxel.
Locally Advanced Breast Carcinoma, Inflammatory Breast Carcinoma, Early Stage HER2-Positive Breast Carcinoma Initial 840 mg IV, then 420 mg IV every 3 weeks with trastuzumab and chemotherapy; neoadjuvant: 3-6 preoperative cycles followed by postoperative continuation to complete 1 year; adjuvant: 1 year total (up to 18 cycles), starting Day 1 of first taxane-containing cycle.
Metastatic HER2-Positive Breast Carcinoma 3.6 mg/kg IV infusion every 3 weeks (21-day cycle) until disease progression or unmanageable toxicity.
Early Stage HER2-Positive Breast Carcinoma 3.6 mg/kg IV infusion every 3 weeks (21-day cycle) for a total of 14 cycles unless disease recurrence or unmanageable toxicity.
Contraindications
- Known hypersensitivity to pertuzumab or any of its excipients
—
Adverse Reactions
Most common (>30%) diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy
Serious neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, fatigue
Most common (>=25%) nausea, fatigue, musculoskeletal pain, hemorrhage, thrombocytopenia, increased transaminases, headache, constipation
Serious hepatotoxicity, left ventricular dysfunction, pulmonary toxicity, infusion-related reactions, hypersensitivity reactions, hemorrhage, thrombocytopenia, peripheral neuropathy
Postmarketing tumor lysis syndrome, skin/tissue necrosis after extravasation, congestive heart failure
Pharmacology
Pertuzumab is a HER2/neu receptor antagonist that blocks ligand-dependent heterodimerization of HER2 with other HER family members (EGFR, HER3, HER4), inhibiting MAP kinase and PI3K signaling pathways to cause cell growth arrest and apoptosis; it also mediates antibody-dependent cell-mediated cytotoxicity (ADCC).
Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate (ADC) consisting of the humanized anti-HER2 IgG1 trastuzumab linked to DM1, a microtubule inhibitor; upon HER2 receptor binding and internalization, intracellularly released DM1 disrupts microtubule networks causing cell cycle arrest and apoptotic cell death, while the antibody component also inhibits HER2 receptor signaling and mediates antibody-dependent cell-mediated cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Perjeta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Kadcyla
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Perjeta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Kadcyla
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Perjeta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Kadcyla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Perjeta.
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PerjetaView full Perjeta profile
KadcylaView full Kadcyla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.